Sign in
Taking people in United StatesNo phase

Cereset brain device tested in stressed caregivers of people with dementia

Tests Cereset for heart rate variability and stress in dementia caregivers.

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Registry title
Cereset Research for Caregivers
Status
Recruiting
People taking part
20 people, planned
Started
16 Jun 2022
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cereset Research
Record updated
1 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who care for someone at least 10 hours per week and have stress, anxiety or sleep problems. The summary describes caregivers of a person living with dementia.

Age
18 Years and older
Sex
All
Disease stage
Self-reported stress, anxiety or insomnia, with a score at or above a set level on at least one questionnaire: Insomnia Severity Index (ISI, ≥ 8), Perceived Stress Index (PSS, ≥ 14), or GAD-7 (≥ 5).
Earlier treatment
No use of the tested technology in the past 3 years. No neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, EMDR or electroconvulsive therapy within the last month.

Main reasons for not taking part

  • Known seizure disorder, or suicidal thoughts within the last 3 months
  • Hearing loss so severe that tones through ear buds cannot be heard
  • Pacemaker, or taking medicines such as beta blockers that affect heart rate variability
  • Weight more than 400 pounds (181 kg)
  • Currently in another intervention study

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Participants must provide caregiving at least 10 hours per week. This includes all types of caregiving
  • participants must be willing to provide informed consent
  • participants must be able to comply with basic instructions
  • participants must be able to sit comfortably for up to 90 minutes, and attend up to three 60-minute intervention sessions each week during the 4-week intervention period
  • participants must self report experiencing symptoms of stress, anxiety, or insomnia and meet threshold scores on one or more self-report inventories of these symptoms (Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale)

Who cannot take part

  • prior use (past 3 years) of the technology being tested
  • prior use of neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, Eye Movement Desensitization and Reprocessing (EMDR),or electroconvulsive therapy within the last month
  • participants with hearing impairment severe enough that they cannot perceive tones through ear buds
  • participants with known seizure disorder, or suicidal thoughts within the last 3 months
  • Pace makers and beta blockers that affect the assessment of heart rate variability will also be exclusionary
  • participants taking Medications that may affect the assessment of heart rate variability (beta blockers
  • participants providing less than 10 hours a week of care to a person
  • participants who are unable or unwilling to attend intervention sessions during the planned study period
  • participants who are unable or unwilling to provide consent
  • participants who are not exhibiting symptoms of stress, anxiety or insomnia
  • participants who respond positively to a question about risk for suicide within the last 3 months will be excluded and receive a behavioral health resource list
  • participants weighing more than 400 pounds (the weight limit of the chair used during intervention)
  • participants currently enrolled in another intervention study

Where in United States

  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Kenzie BrownTaking people

About the trial

What the trial wants to find out

Caregivers experience high levels of prolonged stress that can lead to chronic problems with health, including increased risk of cardiovascular disease that is linked to autonomic dysregulation. Heart rate variability (HRV), measures of autonomic cardiovascular regulation, is decreased (worse) in caregivers. Autonomic function is linked to lateralization in the brain, and emerging neuromodulation methods that target lateralized signals in the brain, like Cereset (CR), may be able to improve heart rate variability. Therefore, this pilot study aims to test whether CR can improve HRV in caregivers of a person living with dementia experiencing stress, anxiety, or insomnia, as well as improve self-report measures of stress, sleep and caregiver burden.

The 2 groups in the trial

  • Cereset ResearchExisting treatment, for comparison

    This will be the active intervention arm using 4 Cereset (CR) sessions and participants will continue current care.

  • ControlSham treatment, for comparison

    Participants will have 4 CR sessions of sham control tones and also continue their current care.

    Treatment: Cereset Research

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cereset Research for Caregivers: A Randomized, Controlled Trial
Plain-language title
Cereset brain device tested in stressed caregivers of people with dementiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
1 June 2026